Momentum Biotechnologies launches CHIPP, a novel high-throughput target deconvolution technology
Novel mass spectrometry based assay enables scalable, label free analysis of drug target interactions
1 Jun 2026Product news
Momentum Biotechnologies (Momentum) has launched CHIPP (Chaotrope-induced protein precipitation and proteome profiling), a novel, sensitive, scalable, and label-free assay for the analysis of drug:target interactions. This technology enables the automated, proteome-wide profiling of hundreds of test compounds, harnessing the analytical capacity of mass spectrometry for target identification, deconvolution, and selectivity profiling.
“We are very excited to launch our new CHIPP technology for scalable and comprehensive target profiling,” says Hannes Hahne, President of Momentum’s European operations.
“Compared to existing label-free target deconvolution methods, CHIPP offers robust increases in both depth and throughput, meaning that scientific teams can obtain more information about more compounds in less time. This assay is a powerful addition to the drug discovery toolbox, and we look forward to accelerating our clients’ research efforts through this new offering.”
Momentum’s Founder and CEO, Can Ozbal, added, “CHIPP has the potential to transform drug discovery workflows – instead of having to select a few candidates for follow-up profiling, researchers can now analyze hundreds of primary screening hits in 96-well-plate format using CHIPP technology. We believe that this approach will offer substantial benefit to our clients and will ultimately facilitate the discovery and development of novel therapeutics.”
Delegates from Momentum will be highlighting CHIPP alongside other service capabilities at this year’s American Society for Mass Spectrometry conference in San Diego, California, from May 31 to June 4.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related products
Request Quote for All Products
CHIPP™
Momentum BiotechnologiesChaotrope-induced protein precipitation & proteome profiling (CHIPP™) is a readily scalable, label-free assay for the study of drug: target interactions.
Frequently asked questions
What is CHIPP technology and how does Momentum Biotechnologies use it in drug discovery?
CHIPP (Chaotrope-induced protein precipitation and proteome profiling) is a novel, sensitive, scalable, label-free assay launched by Momentum Biotechnologies. It leverages mass spectrometry to analyze drug:target interactions and enables automated, proteome-wide profiling of hundreds of test compounds for target identification, deconvolution, and selectivity profiling in drug discovery and development.
How does CHIPP improve label-free target deconvolution compared to existing methods?
According to Hannes Hahne, President of Momentum’s European operations, CHIPP offers robust increases in both depth and throughput versus existing label-free target deconvolution methods. Scientific teams can obtain more information about more compounds in less time, making CHIPP a powerful addition to the drug discovery toolbox for comprehensive target profiling.
How can CHIPP transform drug discovery workflows for primary screening hits?
Momentum’s Founder and CEO, Can Ozbal, states that CHIPP allows researchers to analyze hundreds of primary screening hits in 96-well-plate format. Instead of selecting only a few candidates for follow-up profiling, CHIPP enables scalable, proteome-wide target profiling, which can substantially benefit clients and facilitate the discovery and development of novel therapeutics.